UroGen Pharma (URGN) highlighted results from a long-term, follow-up study with Jelmyto for pyelocalyceal solution, which is FDA approved for the treatment of adults with low-grade, upper tract urothelial cancer. Among patients from the OLYMPUS trial who achieved a complete response after primary chemoablation with Jelmyto, the median duration of response was 47.8 months. The study results were presented at the Society for Urologic Oncology, or SUO, annual meeting in Dallas, Texas, and were recently published online in the Journal of Urology. Of the 71 patients enrolled in OLYMPUS, 41 achieved a complete response after treatment with Jelmyto and had a median duration of response of 47.8 months, with median follow-up of 28.1 months. The analysis has certain limitations, including its post-hoc nature and the inherent selection bias of the 20 patients enrolled in the long-term follow-up study.
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on URGN:
- UroGen Pharma: UGN-102 showed ‘promising’ results in Phase 3 Envision trial
- UroGen Pharma publishes long-term Jelmyto follow-up study results
- UroGen Pharma Reports Q3 Results and Drug Progress
- UroGen Pharma reports Q3 EPS (55c), consensus (82c)
- UroGen Pharma price target raised to $64 from $60 at H.C. Wainwright